CSC-IS
Financiado
Development of a more effective and safer therapeutic antibody for cancer treatm...
Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour s immune system.
Global cancer market is growing at a CAGR of 6.9% with an estimated value of $81bn in 2016. Although the huge R&D investment observed in the past years in the development of new treatments, there is still lack on an effective trea...
Global cancer market is growing at a CAGR of 6.9% with an estimated value of $81bn in 2016. Although the huge R&D investment observed in the past years in the development of new treatments, there is still lack on an effective treatment in many tumour types. In particular, the median survival for glioblastoma multiforme (GBM), a high-grade brain tumour affecting 23,000 patients a year in US and EU, is 14 months and its 5-yr survival less than 5%. It is therefore urgent to develop more effective treatments against this fatal disease.
There are two main reasons that explain the lack of success for the current treatments: In one hand, Cancer Stem cells (CSCs) are responsible from tumour initiation, maintenance, relapse and metastasis. On the other hand, the tumour has mechanisms to repress the patient’s immune system that attacks tumour cells. Our team has discovered a molecular pathway critical in the regulation of CSCs and the immune checkpoint. The project presented here entails the proof of concept and pre-clinical development of a humanized antibody blocking this pathway. At the end of the ERC POC project we will have a patent protected and fully humanized antibody active in vivo and in vitro and ready to enter Phase I clinical trials in humans to continue its commercialization process. The forecasted annual peak revenue for this therapeutic antibody in GBM is $590M with additional sales coming from line extensions in other cancer indications.
With the ERC POC project we are dramatically increasing the commercial value of the therapeutic antibody, transforming an R&D finding (a pathway is critical for cancer) into a potential new solution to patients (a therapeutic antibody). Hence, we are de-risking the product, advancing it through the commercialization path and creating a product and a commercial data package with a good expectative in the cancer market that is ready to be transferred to a spin-off company.
ver más
Duración del proyecto: 18 meses
Fecha Inicio: 2015-06-17
Fecha Fin: 2016-12-31
Fecha Fin: 2016-12-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2016-12-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-PoC-2014:
ERC Proof of Concept Grant
Cerrada
hace 10 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCO...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
16M
Perfil tecnológico
TRL
4-5
16M